&lt;p&gt;Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study&lt;/p&gt;

Wang, Yong; Meng, Xiangwen; Zhou, Shengyan; Zhu, Yufang; Xu, Jun; Tao, Rui

doi:10.2147/ott.s226804

Cited by 18 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang Y et al. reported that, after treatment of apatinib plus temozolomide, 19 recurrent glioblastoma with wild-type IDH got a PFS of 5.9 months and 6m-PFS of 47.4%, which was similar to our study ( 26 ). However, in that study, there was no information about the MGMT methylation status, number of relapse, or tumor dissemination.…”

Section: Discussionsupporting

confidence: 91%

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma

Xue

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTreatment for recurrent glioblastoma is poor, and there is a need for better therapies. Here we retrospectively assessed the efficacy and toxicity of temozolomide plus apatinib, an oral small-molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 in recurrent glioblastoma.Materials and MethodsA retrospective analysis of patients with recurrent glioblastoma who underwent apatinib plus temozolomide treatment was performed. Apatinib was given at 500 mg once daily. Temozolomide was administered at 200 mg/m2/d on days 1–5 or 50 mg/m2/d continuous daily according to whether they had experienced temozolomide maintenance treatment before. The main clinical data collected included tumor characteristics, status of MGMT promoter, and IDH mutation, number of relapse, response, survival, adverse reactions, and salvage therapies.ResultsFrom April 2016 to August 2019, thirty-one patients were identified. The objective response rate was 26.3%, and the disease control rate was 84.2%. The progression-free survival (PFS) at 6 months and overall survival (OS) at 12 months were 44.6 and 30.2%. The median PFS and OS were 4.9 and 8.2 months, respectively. Two patients achieved long PFS of 30.9 and 38.7+ months. The median survival time after progression of the patients with or without salvage bevacizumab was 5.1 versus 1.2 months. The most common grade 3 or 4 toxicities were hypertension (5.8%), decreased appetite (5.8%), and thrombocytopenia (4.3%), most of which were resolved after symptomatic treatment or dose reduction.ConclusionApatinib plus temozolomide is an effective salvage regimen with manageable toxicities for recurrent glioblastoma and could not reduce the sensitivity to bevacizumab.

show abstract

Section: Discussionsupporting

confidence: 91%

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma

Xue

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…There were five patients with SD, so the DCR was 95% (19/20). In addition, the (37). The median follow-up time in our study was only 13.4 months, However, two patients who had no mutation in IDH1 in our study were followed up for more than 15 months, during which their condition remained stable, and there was no progression.…”

Section: Discussionmentioning

confidence: 68%

“…A noncontrolled open study explored the efficacy of apatinib combined with TMZ in the treatment of rGBM. The results showed that both PFS and OS improved, with a median PFS of 6 months (95% CI = 5.3–7.8 months) and a median OS of 9 months (95% CI = 8.2–12.2 months) ( 37 ). Cediranib is a TKI of VEGFR2, C-Kit, and PDGFR.…”

Section: Discussionmentioning

confidence: 99%

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma

She

Shen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeThe purpose of this study was to retrospectively analyze the safety and clinical efficacy of anlotinib combined with dose-dense temozolomide (TMZ) as the first-line therapy in the treatment of recurrent glioblastoma (rGBM).Patients and MethodsWe collected the clinical data of 20 patients with rGBM. All patients received anlotinib (12 mg daily, orally for 2 weeks, discontinued for 1 week, repeated every 3 weeks) combined with dose-dense TMZ (100 mg/m2, 7 days on with 7 days off) until the disease progressed (PD) or adverse effects (AEs) above grade 4 appeared. Grade 3 AEs need to be restored to grade 2 before continuing treatment, and the daily dose of anlotinib is reduced to 10 mg. The patients were reexamined by head magnetic resonance imaging (MRI) every 1 to 3 months. The therapeutic effect was evaluated according to Response Assessment in Neuro-Oncology (RANO) criteria. The survival rate was analyzed by Kaplan-Meier survival curve analysis. The baseline of all survival index statistics was the start of anlotinib combined with dose-dense of TMZ. National Cancer Institute-Common Terminology Criteria Adverse Events version 4.0 (NCI-CTCAE 4.0) was used to evaluate AEs.ResultsTwenty cases of rGBM were evaluated according to the RANO criteria after treatment with anlotinib and dose-dense TMZ, including five cases of stable disease (SD), thirteen cases of partial response (PR), one case of complete response (CR), and one case of PD. The median follow-up time was 13.4 (95% CI, 10.5–16.3) months. The 1-year overall survival (OS) rate was 47.7%. The 6-month progression-free survival (PFS) rate was 55%. In the IDH wild type group, the median PFS and median OS were 6.1 and 11.9 months, respectively. We observed that AEs associated with treatment were tolerable. One patient stopped taking the drug because of cerebral infarction. There were no treatment-related deaths.ConclusionAnlotinib combined with dose-dense TMZ for the first-line therapy showed good efficacy in OS, PFS, ORR, and DCR in the treatment of rGBM, and the AEs were tolerant. Randomized controlled clinical trials investigating the treatment of rGBM with anlotinib are necessary.

show abstract

“…Recently, several approaches to target the TME of brain tumors are ongoing in preclinical and clinical studies. Among them, targeting the vasculature through anti-angiogenic reagents, such as bevacizumab and apatinib, is relatively successful in glioblastoma patients because of highly distributed vessels[ 106 , 107 ]. We have also found that apatinib exhibits efficient effects on the glioblastoma resistant to temozolomide (Figure 3 ).…”

Section: Clinical Applicationmentioning

confidence: 99%

Brain tumors: Cancer stem-like cells interact with tumor microenvironment

Liu

Wang

Feng

2020

WJSC

View full text Add to dashboard Cite

<p>Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study</p>

Cited by 18 publications

References 32 publications

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma

Brain tumors: Cancer stem-like cells interact with tumor microenvironment

Contact Info

Product

Resources

About